2024
Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso
Somé A, Conrad M, Kabré Z, Fofana A, Yerbanga R, Bazié T, Neya C, Somé M, Kagambega T, Legac J, Garg S, Bailey J, Ouédraogo J, Rosenthal P, Cooper R. Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso. Antimicrobial Agents And Chemotherapy 2024, 68: e01534-23. PMID: 38411062, PMCID: PMC10989024, DOI: 10.1128/aac.01534-23.Peer-Reviewed Original ResearchResistance to antifolatesUncomplicated malariaEx vivo drug susceptibilityArtemisinin partial resistanceMonthly sulfadoxine-pyrimethaminePfcrt K76TPfK13 propeller domainResistance-mediating polymorphismsSeasonal malaria chemopreventionTreating uncomplicated malariaResistance to cycloguanilHigh-level resistancePlasmodium falciparum</i>A581GA613S mutationsPfdhps mutationsPfmdr1 N86YArtemether-lumefantrineK76TSulfadoxine-pyrimethamineMalaria chemopreventionPrevent malariaBobo-DioulassoDrug susceptibilityPrincipal therapy
2021
Impact of mass administration of azithromycin as a preventive treatment on the prevalence and resistance of nasopharyngeal carriage of Staphylococcus aureus
Hema-Ouangraoua S, Tranchot-Diallo J, Zongo I, Kabore N, Nikièma F, Yerbanga R, Tinto H, Chandramohan D, Ouedraogo G, Greenwood B, Ouedraogo J. Impact of mass administration of azithromycin as a preventive treatment on the prevalence and resistance of nasopharyngeal carriage of Staphylococcus aureus. PLOS ONE 2021, 16: e0257190. PMID: 34644317, PMCID: PMC8513893, DOI: 10.1371/journal.pone.0257190.Peer-Reviewed Original ResearchConceptsAdministration of azithromycinSerious illnessS. aureusEffectiveness of azithromycinMalaria transmission seasonVulnerable pediatric populationS. aureus isolatesImpact of azithromycinNasal carriageRespiratory infectionsSulfadoxine-pyrimethaminePediatric populationClinical trialsAzithromycin resistanceNasal swabsAureus isolatesTransmission seasonAzithromycinPrevalent strainsMajor causeAdministrationPlaceboStaphylococcus aureusChildrenIllnessEffect of seasonal malaria chemoprevention plus azithromycin on Plasmodium falciparum transmission: gametocyte infectivity and mosquito fitness
Yaméogo K, Yerbanga R, Ouattara S, Yao F, Lefèvre T, Zongo I, Nikièma F, Compaoré Y, Tinto H, Chandramohan D, Greenwood B, Belem A, Cohuet A, Ouédraogo J. Effect of seasonal malaria chemoprevention plus azithromycin on Plasmodium falciparum transmission: gametocyte infectivity and mosquito fitness. Malaria Journal 2021, 20: 326. PMID: 34315475, PMCID: PMC8314489, DOI: 10.1186/s12936-021-03855-3.Peer-Reviewed Original ResearchConceptsAddition of azithromycinMalaria chemopreventionSulfadoxine-pyrimethamineGametocyte infectivityAsexual Plasmodium falciparumDirect membrane feeding assaysSeasonal malaria chemopreventionPlacebo-controlled trialPlasmodium falciparum transmissionMembrane feeding assaysInfectivity of gametocytesControl of malariaPresence of malariaMalaria transmission periodDays post treatmentAnopheles gambiae mosquitoesGametocyte prevalenceMethodsThe studyConclusionThis studyMalaria transmissionP. falciparumControl childrenMosquito transmissionAppropriate interventionsChemoprevention
2017
Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine
Greenwood B, Dicko A, Sagara I, Zongo I, Tinto H, Cairns M, Kuepfer I, Milligan P, Ouedraogo J, Doumbo O, Chandramohan D. Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine. Malaria Journal 2017, 16: 182. PMID: 28464937, PMCID: PMC5414195, DOI: 10.1186/s12936-017-1841-9.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria vaccineTransmission seasonEffective malaria control measuresEffective immunological memoryMalaria transmission seasonHigh transmission seasonMass vaccination campaignMalaria control measuresHigh initial efficacyMalaria chemopreventionSeasonal vaccinationSulfadoxine-pyrimethamineMalaria infectionMalaria treatmentImmunological memoryPilot implementation projectVaccination campaignInitial efficacyFull courseMalaria transmissionVaccineEuropean Medicines AuthorityHealthcare giversMajor cause
2016
Lessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso.
Tinto H, Valea I, Ouédraogo J, Guiguemdé T. Lessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso. Annals Of Parasitology 2016, 62: 17-24. PMID: 27262953, DOI: 10.17420/ap6201.27.Peer-Reviewed Original ResearchConceptsDrug resistanceChloroquine resistanceYear surveillanceSeasonal malaria chemoprophylaxisIntermittent preventive treatmentMalaria drug resistanceSulfadoxine-pyrimethamine resistanceSystematic surveillance systemGood surveillance systemSurveillance systemLate recrudescenceMalaria chemoprophylaxisUncomplicated malariaSulfadoxine-pyrimethamineTreatment failurePregnant womenCombination therapyDevelopment of resistancePreventive treatmentReal prevalenceTreatment resistanceLow prevalenceSentinel sitesAntimalarial drugsBurkina Faso
2015
Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine
Tahita M, Tinto H, Erhart A, Kazienga A, Fitzhenry R, VanOvermeir C, Rosanas-Urgell A, Ouedraogo J, Guiguemde R, Van geertruyden J, D’Alessandro U. Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine. PLOS ONE 2015, 10: e0137440. PMID: 26368675, PMCID: PMC4569438, DOI: 10.1371/journal.pone.0137440.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntimalarialsBurkina FasoDihydropteroate SynthaseDrug CombinationsDrug ResistanceFemaleHumansMalaria, FalciparumMutationPlasmodium falciparumPregnancyPregnancy Trimester, SecondPregnancy Trimester, ThirdPrevalenceProtozoan ProteinsPyrimethamineSulfadoxineTetrahydrofolate DehydrogenaseYoung AdultConceptsIntermittent preventive treatmentPregnant womenPfdhps genesPreventive treatmentAntenatal careSulfadoxine-pyrimethamineThird trimesterDhps mutationsPfdhfr mutationsMalaria infectionMalaria symptomsHealth districtPfdhfr geneBlood samplesSP resistanceI164L mutationEndemic regionsReductase mutationMalaria controlDrug resistancePrevalenceAdverse effectsFive yearsWomenBurkina FasoRandomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso
Zongo I, Milligan P, Compaore Y, Some A, Greenwood B, Tarning J, Rosenthal P, Sutherland C, Nosten F, Ouedraogo J. Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents And Chemotherapy 2015, 59: 4387-4396. PMID: 25918149, PMCID: PMC4505196, DOI: 10.1128/aac.04923-14.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionAlternative drugsControl groupPrimary outcome measureSeasonal malaria transmissionRandomized noninferiority trialPotential alternative drugDihydroartemisinin-PiperaquinePfdhps mutationsClinical malariaMalaria attacksSulfadoxine-pyrimethamineOdds ratioNoninferiority trialOutcome measuresDHAPQChildren 3Malaria transmissionDrug resistanceAntifolate resistanceChemopreventionChildrenAmodiaquineTrials
2014
Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso
Somé A, Zongo I, Compaoré Y, Sakandé S, Nosten F, Ouédraogo J, Rosenthal P. Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents And Chemotherapy 2014, 58: 3660-3665. PMID: 24733476, PMCID: PMC4068591, DOI: 10.1128/aac.02406-14.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionAQ/SPMalaria chemopreventionSingle nucleotide polymorphismsP. falciparum crtPfcrt 76TResistance-mediating polymorphismsMalaria control measuresPCR-positive samplesMonthly DPPfdhfr 108NPfdhfr 51IPfmdr1 86YSulfadoxine-pyrimethamineTreatment armsDevelopment of resistanceTransmission seasonControl groupP. falciparumSNP prevalenceGenetic polymorphismsRegular useAntifolate antimalarialsMonthsBurkina Faso
2007
Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal P, Ouédraogo J. Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso. Clinical Infectious Diseases 2007, 45: 1453-1461. PMID: 17990228, DOI: 10.1086/522985.Peer-Reviewed Original ResearchConceptsUncomplicated Plasmodium falciparum malariaPlasmodium falciparum malariaFalciparum malariaArtemether-lumefantrineRecurrent parasitemiaUncomplicated P. falciparum malariaCombination antimalarial therapyEarly treatment failureSerious adverse eventsP. falciparum malariaDrug-resistant parasitesYears of ageMonths of ageAntimalarial regimenDihydroartemisinin-PiperaquineLumefantrine regimenAdverse eventsCombination regimensSulfadoxine-pyrimethamineRandomized comparisonTreatment failureNew regimenRecurrent malariaAntimalarial therapyTreatment groupsSulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
Tinto H, Ouédraogo J, Zongo I, van Overmeir C, van Marck E, Guiguemdé T, D'Alessandro U. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. American Journal Of Tropical Medicine And Hygiene 2007, 76: 608-13. PMID: 17426157, DOI: 10.4269/ajtmh.2007.76.608.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnimalsAntimalarialsBurkina FasoChildChild, PreschoolChloroquineDrug Administration ScheduleDrug CombinationsDrug ResistanceFemaleGenotypeHumansInfantMalaria, FalciparumMaleMutationPlasmodium falciparumPregnancyPregnancy Complications, ParasiticPyrimethamineSelection, GeneticSulfadoxineTetrahydrofolate DehydrogenaseConceptsSulfadoxine-pyrimethamine efficacyTriple dhfr mutationDHFR mutationsRecurrent parasitemiaIntermittent preventive treatmentSulfadoxine-pyrimethamine resistanceYears of ageSuch high prevalenceDihydropteroate synthetase (Pfdhps) mutationsPCR-restriction fragment length polymorphismSulfadoxine-pyrimethamineTreatment failurePregnant womenPolymerase chain reactionPreventive treatmentHigh prevalenceNew infectionsChain reactionMutant parasitesPatientsParasitemiaTreatmentFragment length polymorphismPrevalenceEfficacy
2006
In vivo sensitivity of Plasmodium faciparum to chloroquine and sulfadoxine pyrimethamine in the Bobo Dioulasso region (1998-2001): risk factors associated with treatments failures to the two drugs.
Tinto H, Sanou B, Erhart A, D'Alessandro U, Ouédraogo J, Guiguemdé T. In vivo sensitivity of Plasmodium faciparum to chloroquine and sulfadoxine pyrimethamine in the Bobo Dioulasso region (1998-2001): risk factors associated with treatments failures to the two drugs. Bulletin De La Société De Pathologie Exotique 2006, 99: 161-5. PMID: 16983817.Peer-Reviewed Original ResearchConceptsCQ treatment failureTreatment failureRisk factorsMultivariate analysisVivo field testTotal treatment failureYears of ageTime of recruitmentSignificant increaseSulfadoxine-pyrimethamineCQ groupUnivariate analysisHealth centersAge of childrenLate failureLow parasitaemiaBetter efficacyDay 14Therapeutic efficacyDay 0SP groupVivo sensitivityParasitaemiaChloroquineDrugs